Warning against the use of static preservation solution due to potential contamination with bacteria

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: On Dec. 14, 2016, staff at a health care facility notified the FDA of an uncharacteristic odor from SPS-1 encountered during an organ procurement operation. Laboratory results from fluid samples and cultures from the SPS-1 used for this operation confirmed contamination with Pantoea and Enterococcus (intrinsically vancomycin-resistant) bacteria.

While it is not yet known how the SPS-1 used for this operation became contaminated, Organ Recovery Systems immediately initiated a voluntary removal of two lots of SPS-1: Lot Numbers PBR-0060-392 and PBR-0074-330.

On Jan. 12, 2017, Organ Recovery Systems notified customers of another report of an uncharacteristic odor from SPS-1 from a different lot, Lot Number PBR-0074-337, suggestive of potential contamination. Additionally, SPS-1 from Lot Number PBR-0060-386 was reported as being present when an odor was noticed, although the report did not identify any odor coming directly from this product.

Since then, Organ Recovery Systems temporarily suspended production and distribution of all SPS-1 products, and added Lot Numbers PBR-0074-337 and PBR-0060-386 to their recall.

On March 8, 2017, Organ Recovery Systems updated customers on the voluntary removal of SPS-1 and stated that additional sterility testing of randomly selected bags of SPS-1 should be completed by March 31, 2017.

To date, there have been no reports to the FDA of any post-operative infections or other adverse events directly linked to the identified products.

BACKGROUND: SPS-1 Static Preservation Solution (SPS-1), manufactured by Organ Recovery Systems, Inc., is a clear to light yellow, sterile solution intended for the flushing and cold storage of kidney, liver, and pancreas at the time of organ removal from the donor in preparation for storage, transportation, and eventual transplantation into a recipient.

The FDA is working with the Centers for Disease Control and Prevention (CDC), the Health Resources and Services Administration (HRSA), and state public health departments to actively investigate the potential for contamination in Organ Recovery Systems’ SPS-1.

 

RECOMMENDATION: In addition to following the standard precautions, the FDA recommends facilities and staff:

  • Be aware that Organ Re...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

FDA Safety Alert - Becton-Dickinson replaced problematic rubber stoppers in its syringes

  • MedWatch Drug Updates
  • 1 comment

Anaphylaxis and other serious hypersensitivity reactions reported with use of Varubi (rolapitant) injectable emulsion

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Reprocessed Agilis Steerable Introducer Sheath by Sterilmed: Improper seal of sheath hub

  • MedWatch Drug Updates
  • no comment

Class I Recall of Certitude Delivery System by Edwards Lifesciences due to a mold overflow defect

  • MedWatch Drug Updates
  • 1 comment

Recall of Ampicillin and Sulbactam for Injection USP, 1.5 g/vial by Auromedics: Presence of glass particles

  • MedWatch Drug Updates
  • 1 comment

Recall of Clopidogrel Tablets, USP 75 mg by International Laboratories due to mislabeling

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Defibrillation Electrodes by Physio-Control: Artwork shows incorrect placement instruction for infants

  • MedWatch Drug Updates
  • 1 comment

Recall of Compounded Sterile Products by PharMEDium Services due to lack of sterility assurance

  • MedWatch Drug Updates
  • 1 comment

Recall of Linezolid Injection 600mg/300mL flexible bags by AuroMedics Pharma: Presence of particulate matter

  • MedWatch Drug Updates
  • 1 comment

Recall of Riomet (Metformin Hydrochloride Oral Solution) by Sun Pharmaceutical: Presence of microbial contamination

  • MedWatch Drug Updates
  • no comment

Recall of Pantoprazole Sodium Injection 40 mg per vial by AuroMedics Pharma: Presence of glass particles

  • MedWatch Drug Updates
  • 1 comment

Long-acting beta agonists and inhaled corticosteroids: FDA removed boxed warning about asthma-related death from labels

  • MedWatch Drug Updates
  • 1 comment

FDA warning: Gadolinium retention in patients body after receiving gadolinium-based contrast agents (GBCAs)

  • MedWatch Drug Updates
  • 1 comment

FDA update: Type III endoleaks associated with the use of endovascular graft systems

  • MedWatch Drug Updates
  • 1 comment

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

  • MedWatch Drug Updates
  • 1 comment

Recall of pharmacist choice alcohol prep pads by simple diagnostics due to quality concerns.

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

  • MedWatch Drug Updates
  • 1 comment

Fading print on label of AlbuRx 25, Albumin (Human) 25% solution

  • MedWatch Drug Updates
  • no comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

  • MedWatch Drug Updates
  • no comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Biotin (Vitamin B7) interferes with certain lab tests

  • MedWatch Drug Updates
  • no comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

  • MedWatch Drug Updates
  • 1 comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

  • MedWatch Drug Updates
  • no comment

FDA investigated life-threatening adverse events associated with Limbrel Capsules by Primus Pharmaceuticals

  • MedWatch Drug Updates
  • 1 comment

Recall of Diphenoxylate Hydrochloride and Atropine Sulfate by Greenstone: Sub-potent or super-potent product

  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

  • MedWatch Drug Updates
  • no comment

FDA safety alert: Increased risk of heart-related death with febuxostat (Uloric)